Sponsor Dossier
Phebra
Sponsor Dossier for Phebra. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ABBOTT
- Brand: ACETADOTE
- Brand: ARAMINE
- Brand: ARGININE
- Brand: ASTRAZENECA
- Brand: Balanced
- Brand: BENZATROPINE INJECTION
- Brand: BENZTROP
- Device (sponsor): Cryogenic spray, cutaneous
About
Phebra is an Australian Private Company with ABN 99059357890, registered in NSW and currently active.
Portfolio
Phebra has 52 brands on the ARTG, of which 39 are indexable and 38 carry a Product Information document. 14 brands are PBS-listed, 5 have a PBAC outcome on record, and 5 have an AusPAR on record. Notable brands include ABBOTT, ACETADOTE, ARAMINE, ARGININE, ASTRAZENECA, Balanced, BENZATROPINE INJECTION, BENZTROP, BREVIBLOC, BUPIVACAINE, CAFNEA, CALDOLOR.
Therapeutic focus
— Other: 10 brands — Pain Management: 10 brands — Cardiology: 7 brands — Endocrinology: 5 brands — Infectious Disease: 5 brands — Neurology: 3 brands — Reproductive Health: 3 brands — Ophthalmology: 2 brands — Oncology: 2 brands — Haematology: 2 brands — Gastroenterology: 1 brand — Psychiatry: 1 brand — Rare Disease: 1 brand
PBS footprint
14 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2018-03-01, across 5 brands with a PBAC outcome on record. The latest AusPAR is 2015-12-23, across 5 brands with an AusPAR on record.